OTCMKTS:AITBAIT Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding AIT Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $7.51 -0.56 (-6.94 %) (As of 05/28/2020 04:00 PM ET) Add Compare Share Today's Range$7.00Now: $7.51▼$8.0450-Day Range$3.94MA: $7.51▼$9.4552-Week Range$3.11Now: $7.51▼$6.25Volume314,214 shsAverage Volume19,435 shsMarket Capitalization$79.46 millionP/E RatioN/ADividend YieldN/ABeta-0.31 ProfileAdvanced ChartCompetitorsEarningsInsider TradesInstitutional OwnershipHeadlinesSocial Media AIT Therapeutics, Inc., a clinical-stage medical device and biopharmaceutical company, develops nitric oxide (NO) delivery systems to treat respiratory and other diseases. Its NO delivery systems are used for the treatment of pulmonary hypertension of the newborn, bronchiolitis, and nontuberculous mycobacteria. The company was founded in 2011 and is based in Garden City, New York.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for AIT Therapeutics. Previous Next 2.3 Community Rank Outperform VotesAIT Therapeutics has received 84 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAIT Therapeutics has received 101 “underperform” votes. (Add your “underperform” vote.)Community SentimentAIT Therapeutics has received 54.59% “underperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about AIT Therapeutics and other stocks. Vote “Outperform” if you believe AITB will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AITB will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAIT Therapeutics does not currently pay a dividend.Dividend GrowthAIT Therapeutics does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AIT Therapeutics insiders have not sold or bought any company stock. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for AIT Therapeutics are expected to grow in the coming year, from ($0.78) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIT Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIT Therapeutics is -2.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 0.0Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.59 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:AITB Previous Symbol CUSIPN/A CIKN/A Webwww.ait-therapeutics.com Phone972-8684-3313Debt Debt-to-Equity RatioN/A Current Ratio2.17 Quick Ratio2.17Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($3.01) Net Income$-18,040,000.00 Net MarginsN/A Return on EquityN/A Return on Assets-100.76%Miscellaneous Employees10 Outstanding Shares10,581,000Market Cap$79.46 million Next Earnings DateN/A OptionableNot Optionable OTC:AITB Rates by TradingView Receive AITB News and Ratings via Email Sign-up to receive the latest news and ratings for AITB and its competitors with MarketBeat's FREE daily newsletter. AIT Therapeutics (OTCMKTS:AITB) Frequently Asked Questions How has AIT Therapeutics' stock been impacted by COVID-19 (Coronavirus)? AIT Therapeutics' stock was trading at $6.41 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AITB shares have increased by 17.2% and is now trading at $7.51. View which stocks have been most impacted by Coronavirus. Has AIT Therapeutics been receiving favorable news coverage? News coverage about AITB stock has been trending somewhat negative on Thursday, according to InfoTrie. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AIT Therapeutics earned a daily sentiment score of -1.8 on InfoTrie's scale. They also gave headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View the latest news aboutAIT Therapeutics. Who are some of AIT Therapeutics' key competitors? Some companies that are related to AIT Therapeutics include SeaSpine (SPNE), Alphatec (ATEC), Iradimed (IRMD), Liquidia Technologies (LQDA), iCAD (ICAD), Pulse Biosciences (PLSE), Accuray (ARAY), Westaim (WEDXF), Soliton (SOLY), Apyx Medical (APYX), TELA Bio (TELA), BeyondAirInc . (XAIR), Restoration Robotics (HAIR), RenovaCare (RCAR) and Venus Concept (VERO). View all competitors. What other stocks do shareholders of AIT Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other AIT Therapeutics investors own include Allena Pharmaceuticals (ALNA), Harvard Bioscience (HBIO), Obseva (OBSV), Anthera Pharmaceuticals (ANTH), Ampliphi Biosciences (APHB), Athersys (ATHX), Deciphera Pharmaceuticals (DCPH), FormFactor (FORM), General Electric (GE) and Professional Diversity Network (IPDN). Who are AIT Therapeutics' key executives? AIT Therapeutics' management team includes the following people: Mr. Steven Adam Lisi, CEO & Chairman (Age 48)Mr. Amir Avniel, Co-Founder, Pres, COO & Director (Age 45)Mr. Douglas J. Beck, Chief Financial Officer (Age 58)Prof. Asher Tal M.D., Sr. VP of Clinical Research & Member of Scientific Advisory BoardDr. Giora Davidai M.D., Chief Medical Officer What is AIT Therapeutics' stock symbol? AIT Therapeutics trades on the OTCMKTS under the ticker symbol "AITB." How do I buy shares of AIT Therapeutics? Shares of AITB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is AIT Therapeutics' stock price today? One share of AITB stock can currently be purchased for approximately $7.51. How big of a company is AIT Therapeutics? AIT Therapeutics has a market capitalization of $79.46 million. The company earns $-18,040,000.00 in net income (profit) each year or ($3.01) on an earnings per share basis. AIT Therapeutics employs 10 workers across the globe. What is AIT Therapeutics' official website? The official website for AIT Therapeutics is www.ait-therapeutics.com. How can I contact AIT Therapeutics? AIT Therapeutics' mailing address is 2 ILAN RAMON SCIENCE PARK, NESS ZIONA L3, 7403635. The company can be reached via phone at 972-8684-3313. This page was last updated on 5/28/2020 by MarketBeat.com Staff
